| Name | Title | Contact Details |
|---|
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
At KBP we are consistently reminded that patient care is the end goal of what we do daily.
Inotiv: (bio)analytical, in vivo, toxicology and molecular pathology services for preclinical drug metabolism in drug development.
PRC is a global leader in AAC Solutions including for individuals with speech disorders. *This group does not provide official technical support.
Braintree Laboratories is a Braintree, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.